JPH06508154A - ペプチド - Google Patents

ペプチド

Info

Publication number
JPH06508154A
JPH06508154A JP5517110A JP51711093A JPH06508154A JP H06508154 A JPH06508154 A JP H06508154A JP 5517110 A JP5517110 A JP 5517110A JP 51711093 A JP51711093 A JP 51711093A JP H06508154 A JPH06508154 A JP H06508154A
Authority
JP
Japan
Prior art keywords
pkc
peptide
activity
array
eggs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5517110A
Other languages
English (en)
Japanese (ja)
Inventor
ディアス−メコ、コンデ，マリエ　テレザ
モスカット，ギレン　ホルヘ
Original Assignee
グラクソ、ソシエダッド、アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソ、ソシエダッド、アノニマ filed Critical グラクソ、ソシエダッド、アノニマ
Publication of JPH06508154A publication Critical patent/JPH06508154A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP5517110A 1992-04-06 1993-04-02 ペプチド Pending JPH06508154A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT92500034.1 1992-04-06
EP92500034 1992-04-06
PCT/EP1993/000816 WO1993020101A1 (en) 1992-04-06 1993-04-02 Inhibitor of protein kinase c

Publications (1)

Publication Number Publication Date
JPH06508154A true JPH06508154A (ja) 1994-09-14

Family

ID=8211817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5517110A Pending JPH06508154A (ja) 1992-04-06 1993-04-02 ペプチド

Country Status (3)

Country Link
EP (1) EP0592634A1 (de)
JP (1) JPH06508154A (de)
WO (1) WO1993020101A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6235723B1 (en) 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
EP0644939A4 (de) * 1993-02-06 1997-08-20 Garvan Inst Med Res Proteinkinase c (jota).
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5648238A (en) * 1996-06-18 1997-07-15 Incyte Pharmaceuticals, Inc. Human protein kinase C inhibitor homolog
ATE439797T1 (de) * 2001-04-27 2009-09-15 Cold Spring Harbor Lab Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität
ATE455185T1 (de) * 2002-11-01 2010-01-15 Univ New York State Res Found Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
EP1877424A4 (de) * 2005-04-11 2010-09-29 Pharmagap Inc Inhibitoren von proteinkinasen und anwendungen davon
EP2298792A3 (de) 2005-08-05 2011-10-19 Pharmagap Inc. Auf Proteinkinase C Isoformen abgezielte Peptide und deren Verwendung
WO2007016777A1 (en) * 2005-08-05 2007-02-15 Pharmagap Inc. Targeted protein kinase c inhibitors and uses thereof
WO2008011621A2 (en) 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability
EP3333176A1 (de) * 2016-12-09 2018-06-13 Universite De Geneve Peptidproteinkinase-c-hemmer und verwendungen davon
CN112334150B (zh) * 2018-06-12 2025-11-18 日内瓦大学 肽蛋白激酶c抑制剂及其用途

Also Published As

Publication number Publication date
WO1993020101A1 (en) 1993-10-14
EP0592634A1 (de) 1994-04-20

Similar Documents

Publication Publication Date Title
JPH06508154A (ja) ペプチド
Sagata et al. Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes
Dinchuk et al. Aspartyl β-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin
JP3193301B2 (ja) 生理活性タンパク質ｐ１６０
US20040146986A1 (en) Runx3 gene showing anti-tumor activity and use thereof
US5994503A (en) Nucleotide and protein sequences of lats genes and methods based thereon
JPH03504916A (ja) 組換え繊維芽細胞成長因子
CN101812127A (zh) 微管结合蛋白及其编码基因与应用
JP2000504933A (ja) ＨＭＧ蛋白質（ｈｉｇｈ ｍｏｂｉｌｉｔｙ ｇｒｏｕｐ ｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用
Mariman et al. Structure and expression of the human creatine kinase B gene
KR102127218B1 (ko) 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
KR20060129504A (ko) 시노비올린 유전자의 프로모터에 대한 디코이 핵산
WO1988009384A1 (en) Method of producing cystatin c or modifications hereof and dna-sequence for use when carrying out the method
JPH06504449A (ja) 合成アルファ−ｌ−イズロニダーゼおよびそれをコード化する遺伝子配列
Gilmore-Hebert et al. Expression of multiple Na+, K+-adenosine triphosphatase isoform genes in human hematopoietic cells. Behavior of the novel A3 isoform during induced maturation of HL60 cells.
KR20010043090A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
US7332335B2 (en) Decreasing cell proliferation by decreasing levels of PP5
CN115607675B (zh) Nav1.9互作蛋白PRMT7及其下调剂在制备镇痛药物中的用途
US5444157A (en) Chondromodulin-I protein
CN113913423B (zh) 人cfap65基因的用途及相关产品
US20050064411A1 (en) Novel gene nedl-1
JP7778495B2 (ja) ウイルスの細胞侵入阻害剤
Langkopf et al. τ and Microtubule‐Associated Protein 2c Transfection and Neurite Outgrowth in ND 7/23 Cells
US20250276036A1 (en) Composition for the inhibition of nrf2 and uses thereof in cancer therapy
CN113917146B (zh) 人pole2基因的用途及相关产品